Adalimumab: A ‘Maillon Faible’ in the Treatment of Ulcerative Colitis?-Reference-Cited by-同舟云学术

Adalimumab: A ‘Maillon Faible’ in the Treatment of Ulcerative Colitis?

Published:2023-10-17 Issue: Volume: Page:
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:

Author:

Roblin Xavier¹,Paul Stephane²^ORCID

Affiliation:

1. Department of Gastroenterology, University Hospital of Saint-Etienne , Saint-Etienne , France

2. Immunology laboratory, iBioThera reference center, CIC1408, University Hospital of Saint-Etienne, Saint-Etienne, France; CIRI (Centre International de Recherche en Infectiologie), Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne , Saint-Etienne , France

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

https://academic.oup.com/ecco-jcc/advance-article-pdf/doi/10.1093/ecco-jcc/jjad167/52208535/jjad167.pdf

Reference11 articles.

1. Prospective observational evaluation of the time-dependency of adalimumab immunogenicity and drug concentration in ulcerative colitis patients: the POETIC II study;Harnik;J Crohns Colitis,2023

2. Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: The POETIC study;Ungar;Am J Gastroenterol,2018

3. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis;Barberio;Gut,2023

4. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis;Lasa;Lancet Gastroenterol Hepatol,2022

5. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial;Colombel;Gastroenterology,2007